Newsroom

Strive to Deliver Breakthroughs

  1. July 26, 2021

    HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021

    Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 26, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that t...

    View more
  2. July 21, 2021

    Mount Sinai Entered into Exclusive License Agreement for Neutralizing SARS-CoV-2 Antibody Derived from Harbour BioMed Technology

    Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 21, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that the I...

    View more
  3. July 20, 2021

    Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 20, 2021   Harbour BioMed (“HBM”, HKEX:02142) announced the appointment of Dr. Yin...

    View more
  4. July 16, 2021

    Harbour BioMed Announces Last Patient Dosing of Phase1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 16, 2021      Harbour BioMed (“HBM”, HKEX: 02142) today announced ...

    View more
  5. July 06, 2021

    Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 6, 2021    Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, subst...

    View more
  6. June 22, 2021

    Harbour BioMed Appoints Amy Que, PhD, as Chief Technology Officer

    Harbour BioMed (HBM) announced the appointment of Dr. Amy Que as Chief Technology Officer (CTO). Dr. Que will lead the Chemistry, Manufacture and Con...

    View more
  7. June 17, 2021

    Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 17, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced the dosing of the f...

    View more
  8. June 16, 2021

    Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

      Cambridge, MA, Rotterdam, NL, Suzhou CN – June 16, 2021   Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-y...

    View more
  9. June 08, 2021

    HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics Conference

    HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics (AET)Conference  (June 8-10, 2021). This anti...

    View more
  10. June 02, 2021

    Capital Group increased its stake in Harbour BioMed to 6.1%

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands -  June 2, 2021 According to public information, on May 31, the C...

    View more